drugset / Trial / NCT06948539
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
Phase 1
Not yet recruiting
66 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
To explore the tolerability and pharmacokinetics of TQB2101 for injection in subjects with advanced malignant tumors.
Timeline
- Start
- 2025-04
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2101 | Other / unclassified | — | — |